+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Amyotrophic Lateral Sclerosis (ALS) - Epidemiology Forecast - 2034- Product Image
Amyotrophic Lateral Sclerosis (ALS) - Epidemiology Forecast - 2034- Product Image
Sale

Amyotrophic Lateral Sclerosis (ALS) - Epidemiology Forecast - 2034

  • PDF Icon

    Report

  • 133 Pages
  • March 2024
  • Region: Global
  • DelveInsight
  • ID: 5204193
UP TO OFF until Dec 31st 2024
Description Jump to:

Key Highlights

  • The analyst's analyst projects that among the total Emergency Visits due to Cocaine in 7MM approximately 55% of cases were from the US, in 2022. The cases are expected to rise in the forecast period, due to factors such as heightened availability of cocaine, changes in societal norms and behaviors, and potentially increased stressors leading to substance abuse.
  • As per the analysis, in 2022, the EU4 and the UK accounted for nearly 308 thousand cases of total emergency visits due to Cocaine, out of which Spain recorded the highest cases, that is nearly 108 thousand cases while Germany recorded the lowest, with nearly 8 thousand cases.
This report delivers an in-depth understanding of the Cocaine Intoxication, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

  • The United States
  • EU4 (Germany, France, Italy, and Spain) and the United Kingdom
  • Japan

Study Period: 2020-2034

Disease Understanding and Diagnostic Algorithm

Cocaine Intoxication Overview

Cocaine intoxication is a condition in which a person is not only high from using the drug but also has body-wide symptoms that can make a person ill and impaired. Cocaine abuse is a major worldwide health problem. Patients with acute cocaine toxicity presenting to the emergency department (ED) may require urgent treatment for tachycardia, dysrhythmia, hypertension, and coronary vasospasm, leading to pathological squeal such as acute coronary syndrome, stroke, and death. Genetic, social, environmental, physical, and mental factors can all play a role when someone gets addicted to cocaine.

Cocaine increases alertness, feelings of well-being, euphoria, energy, sociability, and sexuality. Mild adverse effects include anxiety, increased temperature, paranoia, restlessness, and teeth grinding. The drug can cause chronic complications like insomnia, weight loss, anorexia, persistent tachycardia, heart failure, kidney failure, hallucinations, and paranoid delusions with prolonged use. Furthermore, depression with suicidal ideation may develop in heavy users.

In cases of severe acute intoxication, potentially lethal adverse effects include prolonged episodes of arrhythmia, heavy hypoglycemia, tremors, convulsions, hyperthermia, untreated uremia, myocardial infarction, stroke, and sudden cardiac arrest.

Cocaine Intoxication Diagnosis

The diagnosis of cocaine intoxication includes laboratory testing for suspected cocaine toxicity can include a complete blood count, comprehensive chemistry panel, troponin, B-type natriuretic peptide, creatinine kinase, urinalysis, urine toxicology screen, and electrocardiogram. Imaging may also include chest X-ray, abdominal X-ray for suspected body packers or stuffers, and head CT if altered mental status suggests intracranial hemorrhage. Other diagnostic methods include creatine kinase and urinalysis.

Diagnosing cocaine intoxication poses challenges due to its varied presentation and potential co-occurrence with other substances, necessitating comprehensive clinical assessment and confirmatory drug testing for accurate identification.

Cocaine Intoxication Epidemiology

As the market is derived using the patient-based model, the Cocaine Intoxication epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Emergency Visits due to Cocaine, in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034. As per the analyst's estimations, total emergency visits due to Cocaine in the 7MM were approximately 970 thousand cases in 2022 and these cases are projected to increase during the forecast period.
  • The total emergency visits due to cocaine, in the United States were estimated to be approximately 550 thousand in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).
  • EU4 and the UK accounted for nearly 307 thousand cases of total emergency visits due to cocaine. Among EU4 and the UK, the United Kingdom recorded around 61 thousand cases of total emergency visits due to cocaine and these cases are expected to increase during the forecast period (2023-2034).
  • In Japan, there were around 123 thousand cases of the total emergency visits due to Cocaine, in 2022. Japan accounted around 13% of total emergency visits due to cocaine, in the 7MM. It is anticipated that these numbers will decrease over the study period due to a declining population trend in Japan.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Cocaine Intoxication evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, along with challenges related to accessibility, including KOL from Mayo Medical School, Rochester, Minnesota, United States; Institute für Therapieforschung, München, Germany; Department of Medical Pharmacology and Toxicology, Center for Addictovigilance, Univ Montpellier, Montpellier, France; University of Rome Tor Vertaga, Italy; Emergency Department, Hospital Clinic, Barcelona, Spain; Faculty of Life Sciences and Medicine, King’s College London, London; Pharmaceutical and Food Safety Bureau, Ministry of Health, Labor and Welfare, Tokyo and others.

The analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

  • The report covers a segment of key events, an executive summary, descriptive overview of Cocaine Intoxication, explaining its causes, signs and symptoms, and pathogenesis.
  • Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and guidelines.
  • The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
  • A detailed review of current challenges in establishing the diagnosis.

Cocaine Intoxication Report Insights

  • Patient Population
  • Country-wise Epidemiology Distribution
  • Total Emergency Visits due to Cocaine

Cocaine Intoxication Report Key Strengths

  • 12 years Forecast
  • The 7MM Coverage
  • Cocaine Intoxication Epidemiology Segmentation

Key Questions

Epidemiology Insights

  • What are the disease risks, burdens, and unmet needs of Cocaine Intoxication? What will be the growth opportunities across the 7MM concerning the patient population of Cocaine Intoxication?
  • What is the historical and forecasted Cocaine Intoxication patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
  • Why do only limited patients appear for diagnosis?
  • Which country is more prevalent for Cocaine Intoxication and why?
  • What factors are affecting the diagnosis of the indication?

Reasons to Buy

  • Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • To understand the Cocaine Intoxication prevalence cases in varying geographies over the coming years.
  • A detailed overview of Severity, Gender, and Age-specific prevalence of Cocaine Intoxication.
  • To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
  • Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Cocaine Intoxication Epidemiology report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Cocaine Intoxication cases in 2022?

The highest cases of Cocaine Intoxication was found in the Spain among EU4 and the UK, in 2022.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Cocaine Intoxication cases in 2022?

The highest cases of Cocaine Intoxication were found in the US among the 7MM in 2022.

Table of Contents

1. Key Insights2. Report Introduction
3. ALS Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of ALS in 2023
3.2. Patient Share (%) Distribution of ALS in 2034
4. Epidemiology Forecast Methodology5. Executive Summary
6. Disease Background and Overview
6.1. Introduction
6.2. Types of ALS
6.2.1. Sporadic ALS
6.2.2. Genetic or Familial ALS
6.3. Causes
6.3.1. Genetics
6.3.2. Environmental Factors
6.4. Risk Factors
6.5. Symptoms
6.6. Clinical Features
6.6.1. Clinical Presentation
6.6.2. Amyotrophic Lateral Sclerosis Phenotypes
6.6.3. Subtypes of ALS Based on Relative Umn Versus Lmn Involvement
6.6.4. Subtypes of Motor Neuron Disease Based on the Regional Distribution of Involvement
6.6.5. Subtypes of ALS Based on Additional Frontotemporal Involvement
6.7. Pathogenesis
6.7.1. Failure of Proteostasis
6.7.2. Disturbed RNA Metabolism
6.7.3. Cytoskeletal Disturbances and Axonal Transport Defects
6.8. Biomarker
6.9. Prediction of Prognosis
6.10. Differential Diagnosis
6.11. Diagnosis
7. Epidemiology and Patient Population of the 7MM
7.1. Key Findings
7.2. Assumptions and Rationale
7.3. Total Prevalent Population of ALS in the 7MM
7.4. Total Diagnosed Prevalent Population of ALS in the 7MM
7.5. United States
7.5.1. Diagnosed Prevalence of ALS in the United States
7.5.2. Type-Specific Distribution of ALS in the United States
7.5.3. Gender-Specific Distribution of ALS in the United States
7.5.4. Mutation-Specific Distribution of ALS in the United States
7.5.5. Distribution Based on Site of Onset of ALS in the United States
7.5.6. Age-Specific Distribution of ALS in the United States
7.6. EU4 and UK
7.6.1. Diagnosed Prevalence of ALS in EU4 and the UK
7.6.2. Type-Specific Distribution of ALS in EU4 and the UK
7.6.3. Gender-Specific Distribution of ALS in EU4 and the UK
7.6.4. Mutation-Specific Distribution of ALS in EU4 and the UK
7.6.5. Distribution Based on Site of Onset of ALS in EU4 and the UK
7.6.6. Age-Specific Distribution of ALS in EU4 and the UK
7.7. Japan
7.7.1. Diagnosed Prevalence of ALS in Japan
7.7.2. Type-Specific Distribution of ALS in Japan
7.7.3. Gender-Specific Distribution of ALS in Japan
7.7.4. Mutation-Specific Distribution of ALS in Japan
7.7.5. Distribution Based on Site of Onset of ALS in Japan
7.7.6. Age-Specific Distribution of ALS in Japan
8. Appendix
8.1. Bibliography
8.2. Report Methodology
9. Publisher Capabilities10. Disclaimer11. About the Publisher
List of Tables
Table 1: Summary of Amyotrophic lateral sclerosis (ALS) Epidemiology (2020-2034)
Table 2: List of differential diagnosis and clinical overlap with ALS
Table 3: Summary table of ALS and key differentiating factors with each mimic/variant
Table 4: Diagnostic tests for ALS
Table 5: Revised El Escorial Criteria for ALS
Table 6: Total Prevalent Population of ALS in the 7MM (2020-2034)
Table 7: Total Diagnosed Prevalent Population of ALS in the 7MM (2020-2034)
Table 8: Total Diagnosed Prevalent Population of ALS in the United States (2020-2034)
Table 9: Type-specific Distribution of ALS in the United States (2020-2034)
Table 10: Gender-specific Distribution of ALS in the United States (2020-2034)
Table 11: Mutation-specific Distribution of ALS in the United States (2020-2034)
Table 12: Distribution Based on Site of Onset of ALS in the United States (2020-2034)
Table 13: Age-specific Distribution of ALS in the United States (2020-2034)
Table 14: Diagnosed Prevalence of ALS in EU4 and the UK (2020-2034)
Table 15: Type-specific Distribution of ALS in EU4 and the UK (2020-2034)
Table 16: Gender-specific Distribution of ALS in EU4 and the UK (2020-2034)
Table 17: Mutation-specific Distribution of ALS in EU4 and the UK (2020-2034)
Table 18: Distribution Based on Site of Onset of ALS in EU4 and the UK (2020-2034)
Table 19: Mutation-specific Distribution of ALS in EU4 and the UK (2020-2034)
Table 20: Total Diagnosed Prevalent Population of ALS in Japan (2020-2034)
Table 21: Type-specific Distribution of ALS in Japan (2020-2034)
Table 22: Gender-specific Distribution of ALS in Japan (2020-2034)
Table 23: Mutation-specific Distribution of ALS in Japan (2020-2034)
Table 24: Distribution Based on Site of Onset of ALS in the Japan (2020-2034)
Table 25: Age-specific Distribution of ALS in Japan (2020-2034)
List of Figures
Figure 1: Phenotypic presentations of ALS
Figure 2: Clustering of ALS genes in pathogenic pathways
Figure 3: Total Prevalent Population of ALS in the 7MM (2020-2034)
Figure 4: Total Diagnosed Prevalent Population of ALS in the 7MM (2020-2034)
Figure 5: Diagnosed Prevalence of ALS in the United States (2020-2034)
Figure 6: Type-specific Distribution of ALS in the United States (2020-2034)
Figure 7: Gender-specific Distribution of ALS in the United States (2020-2034)
Figure 8: Mutation-specific Distribution of ALS in the United States (2020-2034)
Figure 9: Distribution Based on Site of Onset of ALS in the United States (2020-2034)
Figure 10: Age-specific Distribution of ALS in the United States (2020-2034)
Figure 11: Diagnosed Prevalence of ALS in EU4 and the UK (2020-2034)
Figure 12: Type-specific Distribution of ALS in EU4 and the UK (2020-2034)
Figure 13: Gender-specific Distribution of ALS in EU4 and the UK (2020-2034)
Figure 14: Mutation-specific Distribution of ALS in EU4 and the UK (2020-2034)
Figure 15: Distribution Based on Site of Onset of ALS in EU4 and the UK (2020-2034)
Figure 16: Age-specific Distribution of ALS in EU4 and the UK (2020-2034)
Figure 17: Diagnosed Prevalence of ALS in Japan (2020-2034)
Figure 18: Type-specific Distribution of ALS in Japan (2020-2034)
Figure 19: Gender-specific Distribution of ALS in Japan (2020-2034)
Figure 20: Mutation-specific Distribution of ALS in Japan (2020-2034)
Figure 21: Distribution Based on Site of Onset of ALS in Japan (2020-2034)
Figure 22: Age-specific Distribution of ALS in Japan (2020-2034)

Related Topics

Related Reports

Amyotrophic Lateral Sclerosis (ALS) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034 - Product Image

Amyotrophic Lateral Sclerosis (ALS) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034

  • Report
  • 128 Pages
  • Global
From
Amyotrophic Lateral Sclerosis (ALS) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Amyotrophic Lateral Sclerosis (ALS) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 267 Pages
  • Global
From
Amyotrophic Lateral Sclerosis Treatment Market Report by ALS Type, Drug Type, Diagnosis Type, Treatment, Distribution Channel, and Region 2024-2032 - Product Image

Amyotrophic Lateral Sclerosis Treatment Market Report by ALS Type, Drug Type, Diagnosis Type, Treatment, Distribution Channel, and Region 2024-2032

  • Report
  • 137 Pages
  • Global
From
Amyotrophic Lateral Sclerosis Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by Treatment Type, Drug, Distribution Channel, Region, By Country: 2020-2030 - Product Image

Amyotrophic Lateral Sclerosis Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by Treatment Type, Drug, Distribution Channel, Region, By Country: 2020-2030

  • Report
  • 309 Pages
  • Global
From
Amyotrophic Lateral Sclerosis - Global Strategic Business Report - Product Image

Amyotrophic Lateral Sclerosis - Global Strategic Business Report

  • Report
  • 183 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.